Hot Investor Mandate: Global Company’s Corporate Venture Arm Strategically Invests in Therapeutics with Strong Interest in Breakthrough Platform Technologies

7 May

A corporate venture arm of a global company seeks to make strategic investments into early-stage companies that are aligned with the company’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. With deep connections into the firm’s global research and development centers, the firm is ideally placed to nurture innovative pharmaceutical companies and to connect these into the parent company.

The firm’s core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, neuroscience and rare disease. The firm is also interested in breakthrough platform technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: